1. Home
  2. AKRO vs OI Comparison

AKRO vs OI Comparison

Compare AKRO & OI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKRO
  • OI
  • Stock Information
  • Founded
  • AKRO 2017
  • OI 1903
  • Country
  • AKRO United States
  • OI United States
  • Employees
  • AKRO N/A
  • OI N/A
  • Industry
  • AKRO Biotechnology: Pharmaceutical Preparations
  • OI Containers/Packaging
  • Sector
  • AKRO Health Care
  • OI Consumer Discretionary
  • Exchange
  • AKRO Nasdaq
  • OI Nasdaq
  • Market Cap
  • AKRO 2.1B
  • OI 2.0B
  • IPO Year
  • AKRO 2019
  • OI N/A
  • Fundamental
  • Price
  • AKRO $32.05
  • OI $11.35
  • Analyst Decision
  • AKRO Strong Buy
  • OI Buy
  • Analyst Count
  • AKRO 7
  • OI 8
  • Target Price
  • AKRO $43.20
  • OI $16.25
  • AVG Volume (30 Days)
  • AKRO 501.9K
  • OI 1.5M
  • Earning Date
  • AKRO 11-15-2024
  • OI 10-29-2024
  • Dividend Yield
  • AKRO N/A
  • OI N/A
  • EPS Growth
  • AKRO N/A
  • OI N/A
  • EPS
  • AKRO N/A
  • OI N/A
  • Revenue
  • AKRO N/A
  • OI $6,643,000,000.00
  • Revenue This Year
  • AKRO N/A
  • OI N/A
  • Revenue Next Year
  • AKRO N/A
  • OI $3.01
  • P/E Ratio
  • AKRO N/A
  • OI N/A
  • Revenue Growth
  • AKRO N/A
  • OI N/A
  • 52 Week Low
  • AKRO $13.39
  • OI $10.08
  • 52 Week High
  • AKRO $37.00
  • OI $17.58
  • Technical
  • Relative Strength Index (RSI)
  • AKRO 62.48
  • OI 36.27
  • Support Level
  • AKRO $30.13
  • OI $11.07
  • Resistance Level
  • AKRO $32.95
  • OI $12.86
  • Average True Range (ATR)
  • AKRO 1.45
  • OI 0.44
  • MACD
  • AKRO 0.14
  • OI -0.17
  • Stochastic Oscillator
  • AKRO 80.26
  • OI 12.79

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.

About OI O-I Glass Inc.

O-I Glass is the world's largest manufacturer of glass bottles; 70% of its revenue comes from outside the United States. O-I has a leading position in key markets such as Europe, North America, and Brazil. Beer is the primary end market for O-I's glass bottles, which are also used for wine, soda, spirits, condiments, and food. O-I is looking to maintain or expand its dominant positions in Europe, North America, and South America.

Share on Social Networks: